Neural Therapeutics (FRA:M6B) Other Stockholders Equity: €0.49 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Other Stockholders Equity?

Neural Therapeutics FRA:M6B Other Stockholders Equity is €0.49 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's Other Stockholders Equity for the quarter that ended in Jan. 2026 was €0.49 Mil.

Neural Therapeutics's quarterly Other Stockholders Equity declined from Jul. 2025 (€0.50 Mil) to Oct. 2025 (€0.49 Mil) but then increased from Oct. 2025 (€0.49 Mil) to Jan. 2026 (€0.49 Mil).

Neural Therapeutics's annual Other Stockholders Equity declined from Jul. 2023 (€0.61 Mil) to Jul. 2024 (€0.36 Mil) but then increased from Jul. 2024 (€0.36 Mil) to Jul. 2025 (€0.50 Mil).

Neural Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Other Stockholders Equity Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Other Stockholders Equity
Get a 7-Day Free Trial -0.00 0.24 0.61 0.36 0.50

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.78 0.50 0.49 0.49

Neural Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.49 Mil mean?
Neural Therapeutics (FRA:M6B) has a Other Stockholders Equity of €0.49 Mil as of Jan. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' Other Stockholders Equity too high?
Neural Therapeutics' current Other Stockholders Equity is €0.49 Mil.
How does Neural Therapeutics' Other Stockholders Equity compare to VRTX and REGN?
Neural Therapeutics' Other Stockholders Equity of €0.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Other Stockholders Equity is €0.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (FRA:M6B) has a current Other Stockholders Equity of €0.49 Mil. The current Other Stockholders Equity is €0.49 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Neural Therapeutics (FRA:M6B), the current Other Stockholders Equity is €0.49 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges NURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.